{"title":"Optimizing radiation therapy for merkel cell carcinoma: evaluating prognostic factors and treatment outcomes.","authors":"Minori Niwa, Masanari Niwa, Natsuo Tomita, Hiromichi Ishiyama, Ayaka Uchida, Yukihiko Oshima, Hirota Takano, Masayuki Matsuo, Mayu Kuno, Akifumi Miyakawa, Shinya Otsuka, Toru Matsui, Shintaro Yamamoto, Taiki Takaoka, Dai Okazaki, Akira Torii, Nozomi Kita, Seiya Takano, Motoki Nakamura, Hiroshi Kato, Akimichi Morita, Akio Hiwatashi","doi":"10.1007/s10147-025-02838-7","DOIUrl":"10.1007/s10147-025-02838-7","url":null,"abstract":"<p><strong>Background: </strong>Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer. Surgery and radiation therapy (RT) are common treatment options; however, an optimal RT strategy has yet to be established. Therefore, the present study examined the outcomes of MCC patients treated with RT, with the aim of elucidating current RT practices and identifying prognostic factors for RT optimization.</p><p><strong>Methods: </strong>This was a retrospective analysis of 32 non-metastatic MCC patients treated with RT. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were calculated using the Kaplan-Meier method. The Log-rank test was used to examine the effect of each factor on outcomes.</p><p><strong>Results: </strong>Median age was 80 years, with a median follow-up period of 26 months. The median dose was 52 Gy in 26 fractions and combined with surgery in 23 patients. Two-year LC, PFS, and OS rates were 94, 61, and 74%, respectively. The Log-rank test showed that tumor size ≥ 5 cm was associated with worse LC (p = 0.03). Male sex and the absence of surgery correlated with worse PFS (p = 0.047 and 0.023, respectively). Performance status ≥ 2, the absence of surgery, and RT margin < 3 cm correlated with worse OS (p = 0.006, 0.02, and 0.02, respectively). RT dose, intensity-modulated RT, and elective nodal irradiation were not associated with any outcomes in this population.</p><p><strong>Conclusion: </strong>RT achieved high local control; however, the metastasis rates were high. A wide RT margin and the combination of RT with surgery may improve the outcomes of MCC patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2148-2156"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Role of cystatin C-based sarcopenia index in predicting postoperative infectious complications after major urologic cancer surgery.","authors":"Ryo Andy Ogasawara, Shugo Yajima, Naoki Imasato, Tomonori Kanagawa, Minoru Inoue, Kohei Hirose, Ken Sekiya, Madoka Kataoka, Yasukazu Nakanishi, Hitoshi Masuda","doi":"10.1007/s10147-025-02828-9","DOIUrl":"10.1007/s10147-025-02828-9","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia has been linked to an increased risk of postoperative complications and poor prognosis in patients undergoing major surgery for urological cancer. The sarcopenia index has emerged as a potential marker of muscle mass. This study investigated the relationship between the sarcopenia index and the occurrence of postoperative infections in patients undergoing major urological surgery.</p><p><strong>Methods: </strong>A total of 416 patients who underwent radical cystectomy, prostatectomy, nephrectomy, partial nephrectomy, or nephroureterectomy between April 2023 and May 2024 were retrospectively analyzed. The sarcopenia index was determined using the following formula: [(serum creatinine/serum cystatin C) × 100]. An optimal threshold for the sarcopenia index was established by using receiver operating characteristic curve analysis. The primary endpoint was the incidence of postoperative infectious complications, including pneumonia, urinary tract infections, and surgical site infections. We also examined the incidence of urinary tract infection and total postoperative complications in the sub-analyses.</p><p><strong>Results: </strong>Of the 416 included patients, 172 (41%) had a sarcopenia index below the determined threshold. Postoperative infectious complications were more in patients with lower sarcopenia index values than in those with higher values (11 vs. 3%, P = 0.0014). However, no significant association was found in the sub-analyses. Multivariate analysis identified a reduced sarcopenia index and contaminated surgical wounds (primarily from radical cystectomy) as independent predictors of postoperative infections.</p><p><strong>Conclusion: </strong>Patients undergoing major urological cancer surgery with a lower sarcopenia index are at an elevated risk of developing postoperative infectious complications. The sarcopenia index may help clinicians predict postoperative infections and improve perioperative management.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2087-2094"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.","authors":"Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Tae Hata, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Koichi Takayama","doi":"10.1007/s10147-025-02837-8","DOIUrl":"10.1007/s10147-025-02837-8","url":null,"abstract":"<p><strong>Background: </strong>In Japan, chemoimmunotherapy was approved as treatment for advanced or recurrent non-small-cell lung cancer (NSCLC), including for patients with epidermal growth factor receptor (EGFR) mutations, in December 2018. However, the impact of its approval on real-world clinical outcomes among patients with EGFR-mutant NSCLC remains unclear. The aim of our study was to assess that impact.</p><p><strong>Methods: </strong>We retrospectively assessed consecutive patients with advanced or recurrent EGFR-mutant NSCLC who received platinum-based cancer therapy after EGFR-tyrosine kinase inhibitors (TKIs) at 20 institutions in Japan from January 2017 to July 2022.</p><p><strong>Results: </strong>We evaluated 120 (27.2%) patients before the chemoimmunotherapy approval and 321 (72.8%) after. Overall, no significant differences in progression-free survival (PFS) or overall survival (OS) were observed between the pre- and post-approval groups (p = 0.72 and p = 0.89, respectively). In the subgroup with programmed cell death-ligand 1 (PD-L1) expression ≥ 50%, the post-approval group had a significantly longer PFS (p = 0.007) and OS (p = 0.048) than the pre-approval group. In contrast, in the PD-L1 < 50% cohort, no significant differences in the PFS (p = 0.54) or OS (p = 0.75) were noted between the groups.</p><p><strong>Conclusions: </strong>The approval of chemoimmunotherapy did not affect treatment outcomes among patients with EGFR-mutant NSCLC who received platinum-based therapy after EGFR-TKIs. However, patients with high levels of PD-L1 expression had improved outcomes post-approval, suggesting potential benefits in this subgroup.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1963-1971"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on: primary tumor location is a risk factor for postoperative development of sarcopenia as a predictive marker for unfavorable outcomes in patients with colorectal cancer.","authors":"Erkan Topkan, Duriye Ozturk, Ugur Selek","doi":"10.1007/s10147-025-02844-9","DOIUrl":"10.1007/s10147-025-02844-9","url":null,"abstract":"","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2157-2158"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical advantages of two vs. three courses of neoadjuvant chemotherapy using docetaxel + cisplatin + 5-fluorouracil to improve preoperative nutritional status and mitigate decreasing skeletal muscle in resectable esophageal cancer.","authors":"Kazuaki Matsui, Yutaka Miyawaki, Ryota Kobayashi, Masatoshi Yoshizawa, Tetsuro Toriumi, Gen Ebara, Hiroshi Sato, Shinichi Sakuramoto","doi":"10.1007/s10147-025-02839-6","DOIUrl":"10.1007/s10147-025-02839-6","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemotherapy (NAC) using docetaxel/cisplatin/5-fluorouracil (DCF) for locally advanced esophageal cancer (EC) showed better clinical outcomes than conventional regimens; however, had high incidence of serious adverse events.</p><p><strong>Methods: </strong>Patients who underwent radical esophagectomy after neoadjuvant-DCF were classified into two-course and three-course groups (n = 60 and 41). Multiple clinical indicators related to nutrition and skeletal muscle that were reported to be associated with survival outcomes were compared between the two groups.</p><p><strong>Results: </strong>Changes in prognostic nutritional index (PNI), geriatric nutritional risk index (GNRI), and psoas muscle area (PMA) were significantly low in the three-course group (p < 0.001, < 0.001, and = 0.003). Multivariate analyses for PNI change rate showed initial PNI < 45 and three-course DCF as independent associated factors (B = 0.129; p < 0.001 and B = - 0.057; p = 0.022); GNRI change rate showed body mass index ≥ 21, initial PNI < 45, and three-course DCF as independent associated factors (B = - 0.033; p < 0.001, B = 0.062; p < 0.001, and B = - 0.059; p < 0.001); PMA change rate showed three-course DCF and cStage IV as independent associated factors (B = - 0.024; p = 0.011 and B = - 0.025; p = 0.038). There were not significant differences in the long-term survivals between the two groups in pStages I-IV.</p><p><strong>Conclusions: </strong>Two courses were superior to three courses for improving nutritional status and mitigating skeletal muscle decreasing during NAC-DCF for EC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1992-2002"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparison of clinical features by primary site in patients with biliary tract cancer who received gemcitabine-based chemotherapy: an exploratory analysis of JCOG1113.","authors":"Yuko Suzuki, Masafumi Ikeda, Junki Mizusawa, Yusuke Sano, Chigusa Morizane, Takuji Okusaka, Satoshi Kobayashi, Hiroshi Imaoka, Takeshi Terashima, Naohiro Okano, Haruo Miwa, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno, Sohei Satoi, Keiji Sano, Kazutoshi Tobimatsu, Akio Katanuma, Masato Ozaka, Makoto Ueno","doi":"10.1007/s10147-025-02834-x","DOIUrl":"10.1007/s10147-025-02834-x","url":null,"abstract":"<p><strong>Background: </strong>Biliary tract cancers (BTCs) are heterogenous malignancies including gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and ampulla of Vater cancer (AVC). The reported data about the differences between the primary sites are limited to data that have just evaluated the efficacy of the treatment arms by primary site in randomized controlled trials. We aimed to compare the clinical features and treatment efficacy among the primary sites of BTCs using data from JCOG1113, a randomized trial.</p><p><strong>Methods: </strong>Among the 354 patients enrolled in JCOG1113, 352 patients were included in this analysis. We compared the patient characteristics, and efficacy outcomes among the primary sites.</p><p><strong>Results: </strong>There were more women (58.4%), and more patients with metastatic disease (78.1%) and multiple organs involving metastases (49.3%) in GBC compared to other primary sites. The median progression-free survival (PFS) was 5.7 months, 6.2 months, 8.7 months and 4.1 months for GBC, IHCC, EHCC and AVC, respectively. The median OS was 12.6 months, 15.7 months, 16.3 months and 11.5 months for GBC, IHCC, EHCC and AVC, respectively. Multivariable analysis revealed that GBC was identified as one of the prognostic factors for PFS compared with EHCC but was not significant for OS.</p><p><strong>Conclusions: </strong>In this study, there were several findings regarding the differences in the clinical features, treatment efficacy, and prognosis among the primary sites. Patients with GBC were more likely to have metastatic disease and multiple metastases. GBC was an independent prognostic factor for PFS compared with EHCC, but was not for OS.</p><p><strong>Clinical trial registration: </strong>JCOG1113 was registered with University hospital Medical Information Network Clinical Trials Regisry (UMIN000010667).</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2053-2062"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kiyoaki Sugiura, Tatsuki Kato, Junya Aoyama, Go Oshima, Hiroto Kikuchi, Koji Okabayashi, Satoshi Aiko, Yuko Kitagawa
{"title":"Predictors of long‑term survival in patients with stage IV colorectal cancer with primary tumor resection: a multi-center retrospective analysis.","authors":"Kiyoaki Sugiura, Tatsuki Kato, Junya Aoyama, Go Oshima, Hiroto Kikuchi, Koji Okabayashi, Satoshi Aiko, Yuko Kitagawa","doi":"10.1007/s10147-025-02845-8","DOIUrl":"10.1007/s10147-025-02845-8","url":null,"abstract":"<p><strong>Background: </strong>Primary tumor resection is an option for patients with stage IV colorectal cancer (CRC). However, there is still no reliable strategy for predicting the survival of individual patients undergoing primary tumor resection (PTR). The aim of this study was to identify predictors of good prognosis in patients with stage IV CRC with PTR.</p><p><strong>Methods: </strong>This is a retrospective analysis of patients with stage IV CRC who had undergone PTR in the Keio Surveillance Epidemiology and End Results (K-SEER) database. Clinical data and short- and long-term outcomes were analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards model including all survival-related variables.</p><p><strong>Results: </strong>Among 252 patients enrolled in this study, 176 had single-organ and 76 had multi-organ metastases. Seventy-seven patients did not receive chemotherapy after primary tumor resection. Three patients consequently underwent curative metastasectomy after PTR. Multivariate Cox analysis revealed age, number of organs with metastasis, and chemotherapy after PTR were independently associated with both Overall Survival (OS) and Cancer-Specific Survival (CSS). In the subgroup analysis, the survival rate was significantly lower in patients with multi-organ metastases than in those with single-organ metastases, both in 3-year OS (47.69% vs 23.20%; log-rank P < 0.001) and 3-year CSS (54.45% vs 30.48%; log-rank P < 0.001).</p><p><strong>Conclusions: </strong>This study demonstrated that multi-organ metastasis was a prognostic factor for poor prognosis in patients with stage IV CRC patients who underwent PTR. These findings could support surgeons to make better clinical decisions for patients with stage IV CRC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2032-2042"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.","authors":"Koshiro Fukuda, Hiroki Osumi, Akira Ooki, Daisaku Kamiimabeppu, Shohei Udagawa, Shota Fukuoka, Mariko Ogura, Takeru Wakatsuki, Keisho Chin, Mitsuhiro Fujishiro, Kensei Yamaguchi, Eiji Shinozaki","doi":"10.1007/s10147-025-02831-0","DOIUrl":"10.1007/s10147-025-02831-0","url":null,"abstract":"<p><strong>Background: </strong>The effect of vascular endothelial growth factor (VEGF) inhibitor pretreatment on clinical outcomes of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC) remains unclear. We aimed to investigate this effect.</p><p><strong>Methods: </strong>Patients with mCRC treated with FTD/TPI plus BEV were retrospectively enrolled. Disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared. In total, 73, 50, and 33 patients were treated with fluorouracil+levofolinate calcium+irinotecan (FOLFIRI) plus BEV, ramucirumab, and aflibercept, respectively.</p><p><strong>Results: </strong>The DCR and median PFS/OS did not significantly differ among the groups (DCR: 54.8% vs. 56.0% vs. 42.4%, P = 0.43; PFS: 3.9 vs. 4.6 vs. 3.7 months, P = 0.45; OS: 12.0 vs. 9.5 vs. 11.9 months, P = 0.28). The most common grade 3-4 AE was neutropenia. The incidence of grade 3-4 AEs did not significantly differ among the groups. The frequency of grade ≥2 proteinuria during FTD/TPI plus BEV treatment was significantly higher in patients with grade ≥2 proteinuria before FOLFIRI plus VEGF inhibitor use than in those without proteinuria. Multivariate analysis revealed poor performance status (ECOG PS) and liver metastasis as independent predictors of short PFS/OS (ECOG PS, PFS: P = 0.021, OS: P < 0.001; liver metastasis, PFS: P = 0.03, OS: P < 0.001) and grade 3-4 neutropenia in a month as a predictor of long PFS/OS (PFS: P = 0.047, OS: P = 0.03).</p><p><strong>Conclusion: </strong>Different pretreatment VEGF inhibitors did not affect the efficacy and safety of FTD/TPI plus BEV.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2022-2031"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A systematic review and meta-analysis of x-ray therapy versus proton beam therapy for pediatric central nervous system germ cell tumors: TRP-Germinoma 2025.","authors":"Sho Hosaka, Masashi Mizumoto, Hiroko Fukushima, Takashi Iizumi, Takashi Saito, Masako Inaba, Ryoko Suzuki, Yinuo Li, Kei Nakai, Shosei Shimizu, Yoshiko Oshiro, Kazushi Maruo, Hidetoshi Takada, Hideyuki Sakurai","doi":"10.1007/s10147-025-02863-6","DOIUrl":"10.1007/s10147-025-02863-6","url":null,"abstract":"<p><strong>Introduction: </strong>Central nervous system germ cell tumors (CNS-GCTs) are rare pediatric tumors, categorized into germinomas and non-germinomatous germ cell tumors (NGGCTs). Proton-beam therapy (PBT) has been introduced as an alternative to X-ray therapy (XRT) for minimizing radiation exposure to normal brain tissue, but evidence comparing these treatment modalities is limited.</p><p><strong>Methods: </strong>A systematic review and meta-analysis following PRISMA guidelines was conducted using PubMed for studies published between 1990 and 2022. Studies reporting overall survival (OS) and progression-free survival (PFS) for CNS-GCTs treated with PBT or XRT were included. Random-effects meta-analyses compared 3- and 5-year OS and PFS between treatment modalities.</p><p><strong>Results: </strong>Forty-one studies were selected, with 36 on XRT and five on PBT. In germinoma patients, no significant differences were found between XRT and PBT for 3-year OS (95.3% vs 97.8%, p = 0.3158), 5-year OS (94.8% vs 97.8%, p = 0.3088), 3-year PFS (90.7% vs 97.1%, p = 0.1045), or 5-year PFS (89.2% vs 91.7%, p = 0.4676). The collected data were insufficient to evaluate PBT in NGGCTs.</p><p><strong>Conclusion: </strong>PBT and XRT showed comparable survival outcomes in germinoma. Further research is required to explore PBT's potential benefits in preserving cognitive function or reducing secondary cancers.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1906-1915"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Burden and trajectories of biliary tract malignancies in Taiwan from 1998 to 2022.","authors":"Chung-Hsin Tsai, I-Hung Chien, Shih-Ping Cheng","doi":"10.1007/s10147-025-02841-y","DOIUrl":"10.1007/s10147-025-02841-y","url":null,"abstract":"<p><strong>Background: </strong>Biliary tract cancers, though relatively rare, exhibit wide variations in incidence rates across countries. We conducted a population-based cohort study to delineate the epidemiological trends over 25 years in Taiwan.</p><p><strong>Methods: </strong>Age-standardized incidence and mortality rates of biliary tract cancers were obtained from the Taiwan Cancer Registry. These cancers were identified using the International Classification of Diseases for Oncology codes C23-C24, which include those originating in the gallbladder and extrahepatic bile ducts while excluding intrahepatic cholangiocarcinomas. The annual percent change (APC) was calculated using joinpoint regression models.</p><p><strong>Results: </strong>Male patients experienced an increasing incidence from 1998 to 2009 (APC = 1.54%) and remained stable thereafter. In contrast, female patients had stable incidence rates from 1998 to 2009, followed by a decrease from 2009 to 2022 (APC = - 1.30%). Age-specific analyses showed that younger generations exhibited a decreasing trend, while the elderly had stable or increasing incidence rates. The proportion of patients receiving surgical treatment declined during the study period, while those undergoing chemotherapy and radiotherapy significantly increased. Mortality rates decreased after 2007.</p><p><strong>Conclusion: </strong>Considerable gender disparities and cohort effects exist in the incidence trends of biliary tract cancers. In addition to surgery, chemotherapy with or without radiation therapy has become an important component of multimodal treatment.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2072-2078"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}